<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE43EBFA-3FC9-44BC-B6FF-001F11664C46"><gtr:id>CE43EBFA-3FC9-44BC-B6FF-001F11664C46</gtr:id><gtr:name>Aarhus University</gtr:name><gtr:address><gtr:line1>Nordre Ringgade 1</gtr:line1><gtr:line4>Aarhus C</gtr:line4><gtr:line5>DK-8000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE43EBFA-3FC9-44BC-B6FF-001F11664C46"><gtr:id>CE43EBFA-3FC9-44BC-B6FF-001F11664C46</gtr:id><gtr:name>Aarhus University</gtr:name><gtr:address><gtr:line1>Nordre Ringgade 1</gtr:line1><gtr:line4>Aarhus C</gtr:line4><gtr:line5>DK-8000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FB0D5D80-307E-4416-B375-470C8C62322F"><gtr:id>FB0D5D80-307E-4416-B375-470C8C62322F</gtr:id><gtr:firstName>Andreas</gtr:firstName><gtr:surname>Wack</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117597139"><gtr:id>A04687CB-3C84-4F23-8FE8-CC68D615D53B</gtr:id><gtr:title>Immune Response to Influenza Infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117597139</gtr:grantReference><gtr:abstractText>We study immune responses to Influenza infection and how the immune system contributes to damage and protection of the patient. Influenza, commonly called the Flu, and other infections of throat and lung are often harmless but sometimes lead to severe damage and even death. Different Flu viruses cause disease of different severity, indicating that viral factors influence disease outcome. Also, when different persons are infected by the same Flu virus, the clinical outcome can vary widely, showing that factors in the individuals body make a difference in the disease. The immune system is necessary to eliminate the virus but in the process contributes to lung damage. The rules in this battle between virus and immune system are not clear, and therefore, the outcome of infection cannot be predicted. Which factors can tip the balance between damage or death on one side and successful clearance of the virus on the other is not completely known. Our studies serve to understand better which characteristics of the virus and of the infected organism can change disease outcome. We attempt to identify factors that contribute to eliciting a strong immune response and to causing lung damage. Better knowledge of these factors will help design better medical intervention during Flu infection.</gtr:abstractText><gtr:technicalSummary>We study early immune events in Influenza infection, specifically the interface between infected lung epithelium and innate immunity. The aim of our studies is to identify determinants of immunogenicity and pathogenicity in influenza virus infection and the immune response to it. Respiratory tract infections by bacteria and viruses are still one of the leading causes of death worldwide. Among these infections, seasonal influenza epidemics represent a constant burden to public health, and influenza pandemics caused by new strains pose a serious global threat. Despite this, it is largely unclear which mechanisms can tip the balance between self-limiting infection on one hand and morbidity and mortality due to lung pathology on the other hand. Influenza virus itself is cytopathic, and the immune response is necessary to eliminate the virus, but also involved in immune-mediated damage to lung tissue. It is still unclear how infected epithelial cells activate the immune system, how early events in the infection influence the induction of the immune response, and which viral and host factors are determinants for a protective or fatal outcome of infection. Work in this programme focuses on these early events and on the relationship between infected epithelial cells and immune cells. We have set up airway epithelial cell cultures from primary cells and now study how they activate innate immunity. In vitro work will be done both with wild-type and mutant murine cells and with human cells. These studies will be complemented by in vivo work using bone-marrow chimeras to assess the contribution of epithelial cells to the onset of anti-influenza immune responses. We will attempt to visualize viral infection by reporter gene strategies, to follow infection in vivo and perform functional tests on infected cells. We will assess the role of NK cells and neutrophils in the immune response to and immunopathology caused by influenza virus infection. Since co-infection by gram-positive bacteria is an important clinical complication of influenza infection, we will determine factors by which the viral infection sets the stage for subsequent bacterial attack. All these studies are instrumental to understand respiratory viral infections better, to predict their outcome and to identify modes of intervention that enhance protection and prevent damage.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2494841</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Mx mice</gtr:description><gtr:id>36B91A77-6591-4625-8787-7024DC7EFB8E</gtr:id><gtr:impact>Publications: 

http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003773
http://embomolmed.embopress.org/content/8/9/1099.long</gtr:impact><gtr:outcomeId>58c2e983ab6537.45714591-1</gtr:outcomeId><gtr:partnerContribution>Provided tissues and animals from genetically modified mouse strains</gtr:partnerContribution><gtr:piContribution>Used tissues and animals provided by the partner in several studies linked to influenza severity and therapy</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aarhus University</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Interferon lambda</gtr:description><gtr:id>ECE7AFC7-6C83-4B10-8C82-E3B53CECB55C</gtr:id><gtr:impact>Publication: http://embomolmed.embopress.org/content/8/9/1099.long</gtr:impact><gtr:outcomeId>58c2e846466761.35875646-1</gtr:outcomeId><gtr:partnerContribution>Provided bioactive purified human and mouse interferon lambda.</gtr:partnerContribution><gtr:piContribution>Used interferons provided for in vivo studies in infection models and in vitro on human cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Streptococcus pneumoniae strains</gtr:description><gtr:id>9B464006-8A34-48F5-81D0-FEA021CF4FC1</gtr:id><gtr:impact>Publication in preparation</gtr:impact><gtr:outcomeId>58c6ab13978a79.78758678-1</gtr:outcomeId><gtr:partnerContribution>Provided range of S.p. strains.</gtr:partnerContribution><gtr:piContribution>Use S.p. strains to understand long-term changes in lung immunity.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Veterinary Medicine (UPenn)</gtr:department><gtr:description>IFNAR1SA mice</gtr:description><gtr:id>4A14FF42-ABEB-4E70-8249-2C404E5FA48B</gtr:id><gtr:impact>common publication in preparation</gtr:impact><gtr:outcomeId>58c2ea6b9d89c2.07525150-1</gtr:outcomeId><gtr:partnerContribution>Provided genetically modified mouse for our studies.</gtr:partnerContribution><gtr:piContribution>Analysed in-depth the genetically modified mouse provided to understand impact of prolonged interferon signalling on influenza severity.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rockefeller University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Serpin E1</gtr:description><gtr:id>7CC2F97A-44E4-4EEB-B556-173E625BC411</gtr:id><gtr:impact>Publication: http://www.sciencedirect.com/science/article/pii/S009286741500118X</gtr:impact><gtr:outcomeId>58c2eb50b8bf32.80683503-1</gtr:outcomeId><gtr:partnerContribution>provided tissues for this analysis</gtr:partnerContribution><gtr:piContribution>Analysed effect of Serpin e1 deficiency in influenza virus control in primary airway epithelia grown from gene-deleted mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Seminar to health professionals about influenza host susceptibility and novel treatment options</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>86299603-32C4-41C0-8C53-68C3431B16EA</gtr:id><gtr:impact>Seminar and discussion at the London-wide Virology discussion group organised by professionals in the clinical sector with the aim of keeping up with recent academic progress. Lively discussion and much interest in the subject and the seminar content.</gtr:impact><gtr:outcomeId>58c2b2a320c481.75001815</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EC70784-EF5D-4254-B97B-5E373EBD43E8</gtr:id><gtr:impact>German national radio station ARD came to find out about the vision of the Crick, how it is to work here as a German researcher and implications of Brexit.</gtr:impact><gtr:outcomeId>58c2aef1e6b3d8.79425807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit to institute</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BDF99267-CB1A-4BDA-AFC5-2EB663603364</gtr:id><gtr:impact>Overview on influenza virus, epidemics and pandemics, and the research concerning influenza we perform here.

school reported high interest and satisfaction of the pupils who attended</gtr:impact><gtr:outcomeId>SuJS1sh6hUF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School class visiting the institute</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>631D85DA-867C-4AB2-8D89-4D1964FC6DD6</gtr:id><gtr:impact>25 pupils were introduced to the research taking place at the NIMR, to raise interest in a career in academic research and the topics covered here.

Following the positive feed back by the class it was agreed to turn this into a regular annual event for subsequent years.</gtr:impact><gtr:outcomeId>TbjtB3TPQtc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4BAE5A9C-1F47-4C35-9BE3-A7048A4B1202</gtr:id><gtr:impact>Interview by BBC 5 radio on our work identifying a molecular link between air pollution and respiratory disease</gtr:impact><gtr:outcomeId>58c2adb0aa5933.03366523</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b07rkgb2</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview to German national newspaper Die Welt</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21C25AC7-861C-46A2-9654-B73225A855F7</gtr:id><gtr:impact>German newspaper Die Welt interviewed me and other colleagues to understand better the new ways of collaboration at the Crick institute</gtr:impact><gtr:outcomeId>58c2b3ab791c71.98234133</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9E390DFB-BD09-4B51-89F3-6197055B4F41</gtr:id><gtr:impact>German national television ARD interviewed about the new Crick institute, working conditions there and Brexit implications.</gtr:impact><gtr:outcomeId>58c2ae615e4179.73182831</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaboration with GSK</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>3A66AC96-5E70-4327-9E34-CBA043113C8E</gtr:id><gtr:outcomeId>A4NPJ84HUT3</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>132000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>44BAC917-296A-40E2-AF14-10E5C7B2A42D</gtr:id><gtr:outcomeId>NrTjzpjVkfm</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>132000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K501475/1</gtr:fundingRef><gtr:id>5C8DFA32-F6EB-4E59-95BE-D3446AED8587</gtr:id><gtr:outcomeId>Yntp19xz1bq</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Based on our preclinical studies, we propose that interferon lambda may be a treatment option for severe influenza, as it has potent antiviral effect and does not show the pro-inflammatory side effects that type I interferons show. In vitro tests on human cells confirm the response patterns we have found in vivo in infection models.</gtr:description><gtr:id>BEC8D85A-6FD2-4926-8DA5-9F5F250D932F</gtr:id><gtr:impact>Based on our preclinical studies, we propose that interferon lambda may be a treatment option for severe influenza, as it has potent antiviral effect and does not show the pro-inflammatory side effects that type I interferons show. In vitro tests on human cells confirm the response patterns we have found in vivo in infection models.</gtr:impact><gtr:outcomeId>58c2b1a5c95a52.68262128</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Interferon lambda as anti-influenza treatment option</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://embomolmed.embopress.org/content/8/9/1099.long</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Lines generated from mouse trachea, can be generated from gene deficient mice</gtr:description><gtr:id>34DBD292-DD33-4A89-B937-C187FA26F28D</gtr:id><gtr:impact>role in influenza infection of single genes can be tested in the primary target cell of the virus</gtr:impact><gtr:outcomeId>RuDkQ6Msf27</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Primary murine airway epithelial cell culture</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Disease model for the major type of lethality-associated infection in pandemic and seasonal influenza waves</gtr:description><gtr:id>6FBEE216-5D08-4973-BC57-F346DE0E78D6</gtr:id><gtr:impact>Allows the study of mechanism behind this common sequela of influenza infection associated with high morbidity and mortality</gtr:impact><gtr:outcomeId>SPWfLKuiaPY</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Murine model of influenza and bacterial co-infection</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F9987269-27F5-4B59-A85C-EB2C51444AB3</gtr:id><gtr:title>Disease-promoting effects of type I interferons in viral, bacterial, and coinfections.</gtr:title><gtr:parentPublicationTitle>Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e40f89bca597264e174cd864c70912df"><gtr:id>e40f89bca597264e174cd864c70912df</gtr:id><gtr:otherNames>Davidson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1079-9907</gtr:issn><gtr:outcomeId>56ba2a872508c3.55347918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>009FF8C7-4B61-40A6-AC4C-A5CEB0E95736</gtr:id><gtr:title>TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed6ca7ad0970781e21082263c30657f"><gtr:id>eed6ca7ad0970781e21082263c30657f</gtr:id><gtr:otherNames>Ellis GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>56ba2a86bd5742.34687521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC895FC-87D9-4190-B90D-EDA946C27163</gtr:id><gtr:title>IFN? is a potent anti-influenza therapeutic without the inflammatory side effects of IFNa treatment.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e40f89bca597264e174cd864c70912df"><gtr:id>e40f89bca597264e174cd864c70912df</gtr:id><gtr:otherNames>Davidson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>58bda7b93258c2.86686643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE6359EC-CA4A-44BD-8B8C-D3483EC715BF</gtr:id><gtr:title>Themis2 is not required for B cell development, activation, and antibody responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a03bfd53f100766fc9d62f8908a13797"><gtr:id>a03bfd53f100766fc9d62f8908a13797</gtr:id><gtr:otherNames>Hartweger H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5458bdc0c762e3.28260182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72F9BF23-E20F-4AB9-ACE2-7CD5705BBB46</gtr:id><gtr:title>Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9590b91c583a8a7a2f84c0e7c103bfc4"><gtr:id>9590b91c583a8a7a2f84c0e7c103bfc4</gtr:id><gtr:otherNames>Redford PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14793_23_23935205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C962B35F-E373-4483-9C04-C28E3D664792</gtr:id><gtr:title>Contribution of cytokines to pathology and protection in virus infection.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/863ba9a68a78985690bfadc5f104bf49"><gtr:id>863ba9a68a78985690bfadc5f104bf49</gtr:id><gtr:otherNames>Wack A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>EkQiCNjgypZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84D0311D-4244-42F4-9929-3A1AAE5AB882</gtr:id><gtr:title>Toll-like receptor 9-independent responsiveness of human monocytes to microbial DNA.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afa86b40bf6f21fbbe496341f2c5c218"><gtr:id>afa86b40bf6f21fbbe496341f2c5c218</gtr:id><gtr:otherNames>Cantisani R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-9475</gtr:issn><gtr:outcomeId>pm_14793_23_24111664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF562426-9DC1-43CE-8A45-B55BFE688334</gtr:id><gtr:title>Vaccinology - Principles and Practice</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107a02bbb634312cf766f3d74016eebc"><gtr:id>107a02bbb634312cf766f3d74016eebc</gtr:id><gtr:otherNames>O'Hagan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>Mj81iM2uPHQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A5A6295-D152-47F7-84EE-55228310F804</gtr:id><gtr:title>Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/157f8298cc7c85d4e6f6c2b50b86a78b"><gtr:id>157f8298cc7c85d4e6f6c2b50b86a78b</gtr:id><gtr:otherNames>Smith N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58bda7b8bb3535.96668549</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC6283A1-D38B-4B1E-B72F-F91BD799F9EC</gtr:id><gtr:title>The transcription factor E4BP4 is not required for extramedullary pathways of NK cell development.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8d7c058fd7f6ebd1229979102230911"><gtr:id>a8d7c058fd7f6ebd1229979102230911</gtr:id><gtr:otherNames>Crotta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5458bdc0539b59.15510122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D78DB6A-4781-4A15-975C-E8503B7055CA</gtr:id><gtr:title>The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2bc2daade7204b0c32c705a148fed78"><gtr:id>e2bc2daade7204b0c32c705a148fed78</gtr:id><gtr:otherNames>Male V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5458bdc07a0a19.90919211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>755177D0-001A-46E8-8AD5-53FA342FB88C</gtr:id><gtr:title>Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4422a88779a5d496d913b4dc18cd76"><gtr:id>5e4422a88779a5d496d913b4dc18cd76</gtr:id><gtr:otherNames>Calabro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>MVyivqsqiHA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>780BE8E5-075F-480F-A5A9-BD6F3B80655A</gtr:id><gtr:title>Pathogenic potential of interferon a? in acute influenza infection.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e40f89bca597264e174cd864c70912df"><gtr:id>e40f89bca597264e174cd864c70912df</gtr:id><gtr:otherNames>Davidson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5458bdc0a08b09.91839590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F7EA95-F4B6-4E4A-B46F-582736C40B77</gtr:id><gtr:title>A serpin shapes the extracellular environment to prevent influenza A virus maturation.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d631f5c7013eefac280ff8be139c2ac2"><gtr:id>d631f5c7013eefac280ff8be139c2ac2</gtr:id><gtr:otherNames>Dittmann M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>56ba2a877d2f32.12311080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00B6146F-713C-4FE4-A9AF-E8A13B948255</gtr:id><gtr:title>The aryl hydrocarbon receptor controls cyclin O to promote epithelial multiciliogenesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f7f2df49a01462b0b60d124fa2844e2"><gtr:id>3f7f2df49a01462b0b60d124fa2844e2</gtr:id><gtr:otherNames>Villa M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58bda7b9017df3.80732101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C7E4C84-9310-47D3-A18E-A15F7088B6FF</gtr:id><gtr:title>Stop the executioners.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/863ba9a68a78985690bfadc5f104bf49"><gtr:id>863ba9a68a78985690bfadc5f104bf49</gtr:id><gtr:otherNames>Wack A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>56ba2a87e33a57.93911416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DCCF351-F31A-4BA4-8C15-305607868F6B</gtr:id><gtr:title>Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee1b1b78cd12dcce0f9b8b9b1e585583"><gtr:id>ee1b1b78cd12dcce0f9b8b9b1e585583</gtr:id><gtr:otherNames>Seubert A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>YTBQr9RtXYb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26810FB0-B621-4AE1-8D76-3469F42730F1</gtr:id><gtr:title>Type I interferons in infectious disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c8b047c051be00c3575d1c495142dfb"><gtr:id>3c8b047c051be00c3575d1c495142dfb</gtr:id><gtr:otherNames>McNab F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>56ba2a87b48c21.38201675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC0B9A20-F9CC-4447-B2AD-857864E86ACF</gtr:id><gtr:title>Guarding the frontiers: the biology of type III interferons.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/863ba9a68a78985690bfadc5f104bf49"><gtr:id>863ba9a68a78985690bfadc5f104bf49</gtr:id><gtr:otherNames>Wack A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>56ba2a86f05583.65969287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF921955-1B9F-441A-9502-679E2D30833F</gtr:id><gtr:title>Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8d7c058fd7f6ebd1229979102230911"><gtr:id>a8d7c058fd7f6ebd1229979102230911</gtr:id><gtr:otherNames>Crotta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>UrWQpeycDtD</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117597139</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>